Sucralfate Tablets USP 1 gram
Product details
- Sucralfate Tablets USP 1 gram
Company announcement
Nostrum Laboratories, Inc. is recalling Sucralfate Tablets USP 1 gram nationwide.
The recall is due to the company's closure and discontinuation of quality activities after filing for Chapter 11 bankruptcy on September 30, 2024.
The company can no longer guarantee the product meets specifications.
The recall affects all lots within expiry manufactured after June 2023.
No adverse events have been reported.
Risk:
The discontinuation of Nostrum Labs’ quality program means that the Company is unable to assure that this product meets the identity, strength, quality, and purity characteristics that it is purported or represented to possess. While specific risks to patients from use of an adulterated product cannot always be identified or assessed, it is also not possible to rule out patient risks resulting from the use of such a product.
Impacted states: Nationwide
Products:
- Sucralfate Tablets USP 1 gram
Contact
For more information, email recallcoordinator@nostrumlabsrecall.com.
Related recalls
- Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) for Intravenous Infusion
- 0.9% Sodium Chloride Injection, USP, 100 mL
- Compounded Glutathione 200 mg/mL 30 mL multidose vial; Myer’s Cocktail 30 mL multidose vial; Tri-Immune Boost 30 mL multidose vial
- Luna G3 APAP (Model LG3600)
- 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container
- 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container